ABCG2gene polymorphisms as risk factors for atorvastatin adverse reactions: a case–control study

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

(2014) L B Ramsey et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phenotype Standardization for Statin-Induced Myotoxicity

(2014) A Alfirevic et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2

(2014) Marco Ferrari et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction

(2014) Maarten Leusink et al.   PHARMACOGENOMICS

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

CYP2C9andABCG2polymorphisms as risk factors for developing adverse drug reactions in renal transplant patients taking fluvastatin: a case–control study

(2013) Nikica Miroševic Skvrce et al.   PHARMACOGENOMICS

PATIENT KNOWLEDGE OF PHARMACOGENETIC INFORMATION IMPROVES ADHERENCE TO STATIN THERAPY: RESULTS OF THE ADDITIONAL KIF6 RISK OFFERS BETTER ADHERENCE TO STATINS (AKROBATS) TRIAL

(2012) Scott L. Charland et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus Conference

(2011) G.B. John Mancini et al.   CANADIAN JOURNAL OF CARDIOLOGY

Case Definition and Phenotype Standardization in Drug-Induced Liver Injury

(2011) G P Aithal et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Clinical Drugs Undergoing Polymorphic Metabolism by Human Cytochrome P450 2C9 and the Implication in Drug Development

(2011) S.-M. He et al.   CURRENT MEDICINAL CHEMISTRY

The Challenge of Exploiting ABCG2 in the Clinic

(2011) Robert W. Robey et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia

(2011) Andreas Holstein et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia

(2011) Paulo Caleb Junior Lima Santos et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort

(2011) Michel R. Hoenig et al.   Journal of Clinical Lipidology

Genomic information as a behavioral health intervention: can it work?

(2011) Cinnamon S Bloss et al.   Personalized Medicine

Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study

(2011) Laure Elens et al.   Pharmacogenetics and Genomics

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin

(2011) L R Brunham et al.   PHARMACOGENOMICS JOURNAL

Genetic involvement in statins induced myopathy. Preliminary data from an observational case–control study

(2010) Luca Puccetti et al.   ATHEROSCLEROSIS

Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go-DARTS Study

(2010) L A Donnelly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy

(2010) Yiannis S. Chatzizisis et al.   DRUG SAFETY

Arlequin suite ver 3.5: a new series of programs to perform population genetics analyses under Linux and Windows

(2010) LAURENT EXCOFFIER et al.   Molecular Ecology Resources

Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs

(2010) D Wang et al.   PHARMACOGENOMICS JOURNAL

Transporter Pharmacogenetics and Statin Toxicity

(2009) M Niemi   CLINICAL PHARMACOLOGY & THERAPEUTICS

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance

(2009) Bo Wang et al.   CURRENT DRUG METABOLISM

Oral Sulfasalazine as a Clinical BCRP Probe Substrate: Pharmacokinetic Effects of Genetic Variation (C421A) and Pantoprazole Coadministration

(2009) Kimberly K. Adkison et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

The SLCO1B1*5Genetic Variant Is Associated With Statin-Induced Side Effects

(2009) Deepak Voora et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effects of α-Adrenoceptor Antagonist Doxazosin on MDR1-Mediated Multidrug Resistance and Transcellular Transport

(2009) Kohji Takara et al.   ONCOLOGY RESEARCH

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

ABCG2: A perspective

(2008) Robert W. Robey et al.   ADVANCED DRUG DELIVERY REVIEWS

Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy

(2008) Kunihiro Suzuki et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin

(2008) J.-E. Park et al.   XENOBIOTICA